The fight against covid

The British company's vaccine had an average efficiency of 70%, but one of the methods of administration showed a 90% efficiency.

AZD 1222 vaccine against coronavirus infection COVID-19, which is being developed in the UK, showed high efficiency during the tests, says the pharmaceutical company AstraZeneca. The company explained that during the tests two variants of the vaccine were tested demonstrated different efficiency.

In the first case, AZD 1222 administered to more than 2,700 people in half a dose first and a month later in full. This method of vaccination showed 90% efficacy, while the full-dose option with a montly difference of almost 9,000 test subjects was given only 62%.

The company stated that the average efficiency of the vaccine, taking into account the data from both tests, was 70 percent.

According to Professor Andrew Pollard, who led the vaccine trials in Oxford, the test results confirmed that AZD1222 can save many lives.

A. Pollard also said: "With one of the options, the vaccine can be effective by about 90%, and with the same vaccine volume, more people can be vaccinated".

AstraZeneca noted that a total of 131 cases of infection of participants in the COVID-19 trials were identified. At the same time, none of those who were ill had a serious illness and none of them needed to be hospitalised. The independent Data Safety Review Board confirmed, however, that the immunity required from protection against COVID-19 is produced 14 days after the second dose of vaccine and that no serious side effects were detected during the tests.

In November, other developers also reported on the high effectiveness of their version of the COVID-19 vaccine. For example, American Moderna estimated the effectiveness of its product at 94.5%, and Pfizer and BioNTech at 95%.